ZyVersa Therapeutics Reports $19.8 Million Net Loss and Faces Delisting Challenges

ZyVersa Therapeutics, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of approximately $19.8 million for the third quarter, a substantial increase from a loss of $2.4 million during the same period in 2024. For the nine months ending September 30, 2025, the total net loss reached approximately $24.3 million, compared to $8.0 million for the corresponding period in 2024. The increase in losses is attributed primarily to an $18.6 million impairment charge related to in-process research and development, reflecting a significant decline in the company's market capitalization.

In terms of operational metrics, ZyVersa's total operating expenses surged to $20.8 million for the third quarter of 2025, compared to $2.3 million in the prior year, marking an increase of 814.6%. Research and development expenses decreased slightly to $0.4 million, down 16.3% from the previous year, while general and administrative expenses also saw a minor reduction of 5.1%. The company’s accumulated deficit has now reached approximately $136.9 million, with cash reserves dwindling to $0.5 million as of September 30, 2025, down from $1.5 million at the end of 2024.

Strategically, ZyVersa has faced challenges in maintaining its listing on the Nasdaq Capital Market, leading to its delisting on October 6, 2025. The company has since transitioned to trading on the OTCQB Venture Market. In an effort to bolster its financial position, ZyVersa entered into an Equity Purchase Agreement in June 2025, allowing it to sell up to $10 million in common stock. The company also reported a significant increase in its common stock issuance, with 8,095,928 shares outstanding as of September 30, 2025, compared to 2,508,198 shares at the end of 2024.

Looking ahead, ZyVersa anticipates continued operating losses as it progresses with the development of its drug candidates, VAR 200 and IC 100, which target chronic renal and inflammatory diseases. The company expects to incur substantial expenses related to regulatory submissions, clinical trials, and operational costs. Management has indicated that additional financing will be necessary to support ongoing operations and development efforts, although there is no assurance that such funding will be available on favorable terms. The company’s ability to achieve profitability remains uncertain, hinging on the successful development and commercialization of its product candidates.